Arca Biopharma (ABIO) vs. Trinity Biotech (TRIB) Financial Analysis

Arca Biopharma (NASDAQ:ABIO) and Trinity Biotech (NASDAQ:TRIB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, analyst recommendations and risk.

Risk & Volatility

Arca Biopharma has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500. Comparatively, Trinity Biotech has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500.

Institutional and Insider Ownership

15.7% of Arca Biopharma shares are held by institutional investors. Comparatively, 68.4% of Trinity Biotech shares are held by institutional investors. 3.6% of Arca Biopharma shares are held by company insiders. Comparatively, 8.2% of Trinity Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Arca Biopharma and Trinity Biotech, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arca Biopharma 0 0 1 0 3.00
Trinity Biotech 0 0 0 0 N/A

Arca Biopharma presently has a consensus target price of $2.00, indicating a potential upside of 284.62%. Given Arca Biopharma’s higher possible upside, equities research analysts plainly believe Arca Biopharma is more favorable than Trinity Biotech.

Profitability

This table compares Arca Biopharma and Trinity Biotech’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Arca Biopharma N/A -112.69% -97.53%
Trinity Biotech -42.24% 3.74% 1.30%

Valuation and Earnings

This table compares Arca Biopharma and Trinity Biotech’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Arca Biopharma N/A N/A -$18.49 million N/A N/A
Trinity Biotech $99.14 million 0.70 -$40.27 million N/A N/A

Arca Biopharma has higher earnings, but lower revenue than Trinity Biotech.

Arca Biopharma Company Profile

ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. The company's lead product candidate is Gencaro, a pharmacologically beta-blocker and mild vasodilator, which is in clinical trial for the treatment of atrial fibrillation in chronic heart failure patients with reduced left ventricular ejection fraction. It also engages in the development of a preclinical plan for AB171, a new chemical entity for the treatment of various cardiovascular indications, such as peripheral arterial disease and chronic heart failure. The company has a collaboration agreement with Medtronic, Inc. for the support of GENETIC-AF Phase 2B clinical trials; and Laboratory Corporation of America to provide the companion diagnostic test and services to support GENETIC-AF trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

Trinity Biotech Company Profile

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease, sexually transmitted diseases, respiratory infections, epstein barr virus, and other viral pathogens; and products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a high risk of developing diabetes. It also develops, manufactures, and distributes products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research industries. The company sells its products through its direct sales force in the United States; and a network of independent distributors and strategic partners internationally. Its customers include public health facilities, hospitals, and other outreach facilities, as well as clinical and reference laboratories. Trinity Biotech plc was founded in 1992 and is headquartered in Bray, Ireland.

Receive News & Ratings for Arca Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arca Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit